266 related articles for article (PubMed ID: 29068145)
1. Validation of the prognostic power of the RETREAT score for hepatocellular carcinoma recurrence using the UNOS database.
Mehta N; Dodge JL; Roberts JP; Yao FY
Am J Transplant; 2018 May; 18(5):1206-1213. PubMed ID: 29068145
[TBL] [Abstract][Full Text] [Related]
2. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
Mehta N; Heimbach J; Harnois DM; Sapisochin G; Dodge JL; Lee D; Burns JM; Sanchez W; Greig PD; Grant DR; Roberts JP; Yao FY
JAMA Oncol; 2017 Apr; 3(4):493-500. PubMed ID: 27838698
[TBL] [Abstract][Full Text] [Related]
3. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.
Mehta N; Dodge JL; Grab JD; Yao FY
Hepatology; 2020 Mar; 71(3):943-954. PubMed ID: 31344273
[TBL] [Abstract][Full Text] [Related]
4. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
[TBL] [Abstract][Full Text] [Related]
5. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
6. Liver transplantation for HCC: validation of prognostic power of the RETREAT score for recurrence in a UK cohort.
Reddy SHS; Mehta N; Dodge JL; Hakeem AR; Khorsandi SE; Jassem W; Vilca-Melendez H; Cortes-Cerisuelo M; Srinivasan P; Prachalias A; Heneghan MA; Aluvihare V; Suddle A; Miquel R; Rela M; Heaton ND; Menon KV
HPB (Oxford); 2022 May; 24(5):596-605. PubMed ID: 34702624
[TBL] [Abstract][Full Text] [Related]
7. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
[TBL] [Abstract][Full Text] [Related]
8. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
[TBL] [Abstract][Full Text] [Related]
9. Early Detection of Hepatocellular Carcinoma Recurrence in the Posttransplant Population: A Comparison of RETREAT and Cleveland Clinic Florida Scoring System.
Hasan B; Colak Y; Khalid RA; Castillo M; Castaneda D; Tandon K; Shaw JJ; Erim T; Zervos XB; Castro FJ; Al-Khalloufi K
Transplant Proc; 2021; 53(1):193-199. PubMed ID: 33069486
[TBL] [Abstract][Full Text] [Related]
10. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
[TBL] [Abstract][Full Text] [Related]
11. Downstaging Outcomes for Hepatocellular Carcinoma: Results From the Multicenter Evaluation of Reduction in Tumor Size before Liver Transplantation (MERITS-LT) Consortium.
Mehta N; Frenette C; Tabrizian P; Hoteit M; Guy J; Parikh N; Ghaziani TT; Dhanasekaran R; Dodge JL; Natarajan B; Holzner ML; Frankul L; Chan W; Fobar A; Florman S; Yao FY
Gastroenterology; 2021 Nov; 161(5):1502-1512. PubMed ID: 34331914
[TBL] [Abstract][Full Text] [Related]
12. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
Vutien P; Dodge J; Bambha KM; Nordstrom EM; Gralla J; Campbell K; Levek C; Nydam T; Fix O; Ioannou G; Biggins SW
Liver Transpl; 2019 Apr; 25(4):559-570. PubMed ID: 30706653
[TBL] [Abstract][Full Text] [Related]
13. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.
Kornberg A; Schernhammer M; Kornberg J; Friess H; Thrum K
Dig Dis Sci; 2019 Jan; 64(1):269-280. PubMed ID: 30259282
[TBL] [Abstract][Full Text] [Related]
14. Radiological-histopathological discordance in patients transplanted for HCC and its impact on post-transplant outcomes.
Mohamed IB; Ismail MS; El Sabagh A; Afifi Abdelwahab AM; Polychronopoulou E; Kuo YF; Hassan M; Goss JA; Kanwal F; Jalal PK
Cancer Med; 2023 Jul; 12(14):15011-15025. PubMed ID: 37326440
[TBL] [Abstract][Full Text] [Related]
15. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
Duvoux C; Roudot-Thoraval F; Decaens T; Pessione F; Badran H; Piardi T; Francoz C; Compagnon P; Vanlemmens C; Dumortier J; Dharancy S; Gugenheim J; Bernard PH; Adam R; Radenne S; Muscari F; Conti F; Hardwigsen J; Pageaux GP; Chazouillères O; Salame E; Hilleret MN; Lebray P; Abergel A; Debette-Gratien M; Kluger MD; Mallat A; Azoulay D; Cherqui D;
Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
[TBL] [Abstract][Full Text] [Related]
16. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of hepatocellular carcinoma recurrence after liver transplantation: accuracy of the alpha-fetoprotein model in a single-center experience.
Varona MA; Soriano A; Aguirre-Jaime A; Garrido S; Oton E; Diaz D; Portero J; Bravo P; Barrera MA; Perera A
Transplant Proc; 2015; 47(1):84-9. PubMed ID: 25645778
[TBL] [Abstract][Full Text] [Related]
18. Histological differentiation predicts post-liver transplantation survival time.
Li WX; Li Z; Gao PJ; Gao J; Zhu JY
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):201-8. PubMed ID: 24388339
[TBL] [Abstract][Full Text] [Related]
19. The RETREAT score provides valid predictions regarding hepatocellular carcinoma recurrence after liver transplantation.
Åberg F; Abrahamsson J; Schult A; Bennet W; Rizell M; Sternby-Eilard M
Transpl Int; 2021 Dec; 34(12):2869-2874. PubMed ID: 34779038
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.
Lee DH; Lee JM; Baek JH; Shin CI; Han JK; Choi BI
Radiology; 2015 Jan; 274(1):149-60. PubMed ID: 25203131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]